Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is a Healthcare company (Biotechnology) with a market capitalization of $70M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Tonix Pharmaceuticals Holding Corp. had a Maz Rating of 3.03 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Growth (4.48), above most of its sector; its weakest was Momentum (2.02), below most of its sector. The other factors: Valuation 3.95 (more attractively valued than most of its sector); Financial Health 3.65 (above most of its sector); Profitability 2.20 (below most of its sector). The current rating is for members: log in to see it.
At $4.10, Tonix Pharmaceuticals Holding Corp. trades at 1.6x sales and 0.4x book value, with an EV/EBITDA of 0.5. Over the last twelve months it generated about $43M of revenue and a net loss of $214M. It runs a gross margin of 86.9%, an operating margin of -436.3% and a net margin of -296.6%. It shows return on equity of -57.1%, return on invested capital of -93.5% and a free cash flow yield of -235.2%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 4.57. Over the past 52 weeks the share price ranged from $4.00 to $20.56, with a beta of 1.90.
Tonix Pharmaceuticals Holding Corp. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.